171 related articles for article (PubMed ID: 12200608)
1. Severe Coxsackie virus B infection in preterm newborns treated with pleconaril.
Bauer S; Gottesman G; Sirota L; Litmanovitz I; Ashkenazi S; Levi I
Eur J Pediatr; 2002 Sep; 161(9):491-3. PubMed ID: 12200608
[TBL] [Abstract][Full Text] [Related]
2. Neonatal coxsackie B virus infection-a treatable disease?
Bryant PA; Tingay D; Dargaville PA; Starr M; Curtis N
Eur J Pediatr; 2004 Apr; 163(4-5):223-8. PubMed ID: 14986123
[TBL] [Abstract][Full Text] [Related]
3. Antiviral treatment of Coxsackie B virus infection in human pancreatic islets.
Berg AK; Olsson A; Korsgren O; Frisk G
Antiviral Res; 2007 Apr; 74(1):65-71. PubMed ID: 17239967
[TBL] [Abstract][Full Text] [Related]
4. [Polio-like myelitis due to Coxsackie-Virus B 3: Course under treatment with pleconaril].
Utzig N; Friedrich B; Burtzlaff C; Lauffer H
Klin Padiatr; 2003; 215(5):286-7. PubMed ID: 14520593
[TBL] [Abstract][Full Text] [Related]
5. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection.
Schiff GM; Sherwood JR
J Infect Dis; 2000 Jan; 181(1):20-6. PubMed ID: 10608746
[TBL] [Abstract][Full Text] [Related]
6. Investigation of treatment failure in neonatal echovirus 7 infection.
Rentz AC; Libbey JE; Fujinami RS; Whitby FG; Byington CL
Pediatr Infect Dis J; 2006 Mar; 25(3):259-62. PubMed ID: 16511392
[TBL] [Abstract][Full Text] [Related]
7. Severe neonatal enteroviral hepatitis treated with pleconaril.
Aradottir E; Alonso EM; Shulman ST
Pediatr Infect Dis J; 2001 Apr; 20(4):457-9. PubMed ID: 11332680
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of enterovirus infection with the use of pleconaril in 2 infants with severe combined immunodeficiency.
Nowak-Wegrzyn A; Phipatanakul W; Winkelstein JA; Forman MS; Lederman HM
Clin Infect Dis; 2001 Jan; 32(1):E13-4. PubMed ID: 11112666
[TBL] [Abstract][Full Text] [Related]
9. Effect of consecutive alternating administration (CAA) of a triple anti-enteroviral combination on Coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Galabov AS
Antiviral Res; 2015 Sep; 121():138-44. PubMed ID: 26196747
[TBL] [Abstract][Full Text] [Related]
10. Therapy of coxsackie virus B3-induced myocarditis with WIN 54954 in different formulations.
Pauksen K; Ilbäck NG; Friman G; Fohlman J
Scand J Infect Dis Suppl; 1993; 88():125-30. PubMed ID: 8390715
[TBL] [Abstract][Full Text] [Related]
11. Activity of pleconaril against enteroviruses.
Pevear DC; Tull TM; Seipel ME; Groarke JM
Antimicrob Agents Chemother; 1999 Sep; 43(9):2109-15. PubMed ID: 10471549
[TBL] [Abstract][Full Text] [Related]
12. Anti-enteroviral triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Pürstinger G; Dobrikov G; Dimitrov V; Philipov S; Galabov AS
Antivir Chem Chemother; 2015 Dec; 24(5-6):136-147. PubMed ID: 27815331
[TBL] [Abstract][Full Text] [Related]
13. Treatment of potentially life-threatening enterovirus infections with pleconaril.
Rotbart HA; Webster AD;
Clin Infect Dis; 2001 Jan; 32(2):228-35. PubMed ID: 11170912
[TBL] [Abstract][Full Text] [Related]
14. [Myocarditis and meningoencephalitis in newborn infants caused by Coxsackie virus B 3].
LUKES J
Cesk Pediatr; 1959 Aug; 14():731-5. PubMed ID: 14418848
[No Abstract] [Full Text] [Related]
15. Pleconaril revisited: clinical course of chronic enteroviral meningoencephalitis after treatment correlates with in vitro susceptibility.
Wildenbeest JG; van den Broek PJ; Benschop KS; Koen G; Wierenga PC; Vossen AC; Kuijpers TW; Wolthers KC
Antivir Ther; 2012; 17(3):459-66. PubMed ID: 22293148
[TBL] [Abstract][Full Text] [Related]
16. Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus.
Pinkert S; Dieringer B; Diedrich S; Zeichhardt H; Kurreck J; Fechner H
Antiviral Res; 2016 Dec; 136():1-8. PubMed ID: 27773751
[TBL] [Abstract][Full Text] [Related]
17. Phyllaemblicin B inhibits Coxsackie virus B3 induced apoptosis and myocarditis.
Wang YF; Wang XY; Ren Z; Qian CW; Li YC; Kaio K; Wang QD; Zhang Y; Zheng LY; Jiang JH; Yang CR; Liu Q; Zhang YJ; Wang YF
Antiviral Res; 2009 Nov; 84(2):150-8. PubMed ID: 19699238
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary hemorrhage due to Coxsackievirus B infection-A call to raise suspicion of this important complication as an end-stage of enterovirus sepsis in preterm twin neonates.
Orbach R; Mandel D; Lubetzky R; Ovental A; Haham A; Halutz O; Grisaru-Soen G
J Clin Virol; 2016 Sep; 82():41-45. PubMed ID: 27434146
[TBL] [Abstract][Full Text] [Related]
20. [Effect of a C-type CpG ODN on CVB3-infected mice].
Yang L; Sun WQ; Wang L; Wang XL; Wan M; Yu YL; Wang LY
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Feb; 25(2):115-7. PubMed ID: 19174007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
